Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus

Exclusion Criteria

• •Any one of the following
• •1. Patients with decompensated liver disease of any etiology(characterized by elevated bilirubin, raised International normalized ratio, or a history of ascites, variceal hemorrhage,hepatic encephalopathy, Spontaneous bacterial peritonitis, hepatorenal syndrome or Hepatocellular carcinoma)
• •2. Family history of hepatocellular carcinoma
• •3. Patients with HIV and Hepatitis C virus co-morbidity
• •4. Pregnant, attempting to conceive, or lactating women
• •5. Patients with diabetes mellitus
• •6. Recent history of acute coronary syndrome (\<6months) or chronic coronary artery disease with poor left ventricular function (by physician / cardiology opinion)
• •7. Patients with renal failure ( Creatinine clearance less than 60 ml/min)
• •8. Active substance or alcohol abuse and concurrent use of corticosteroids or immunosuppressive agents.
• •9. Presence of extra hepatic manifestations
• •10. Previously treated with pegylated interferon within the last 2 years
• •11. Positive fibroscan or ultrasound elastography showing evidence of fibrosis (F3 and above)
• •12. Current or former employees of organic India
• •13. Participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days.
• •14. Refusing consent or physician uncomfortable with patient compliance to treatments or follow up.